JNJ · Johnson & Johnson
$263.81
-1.42% last session
End-of-day data · close of 2026-10-23
Market cap
$635B
Enterprise value
$664B
Trailing P/E
40.0
Forward P/E
22.7
Dividend yield
2.0%
Beta
0.21
Avg volume
7M
Employees
138K
Daily Change %
-1.42%
5 Days Change
4.72%
10 Days Change
7.64%
30 Days Change
-0.58%
60 Days Change
-1.51%
Month to Day Change
3.46%
Year to Day Change
31.39%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — JNJ
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-16
Latest call per bank · past 12 months
Wells Fargo
Overweight$287
+8.8% vs priceMorgan Stanley
Overweight$292
+10.7% vs priceRBC Capital
Outperform$280
+6.1% vs priceCitigroup
Buy$303
+14.9% vs priceJP Morgan
Neutral$285
+8.0% vs priceHSBC
Buy$320
+21.3% vs priceUBS
Buy$320
+21.3% vs priceBank of America
Neutral$263
-0.3% vs priceBarclays
Equal-Weight$255
-3.3% vs priceGoldman Sachs
Buy$240
-9.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-16 | Wells Fargo | Maintains | Overweight | $275 → $287 |
| 2026-10-15 | Morgan Stanley | Maintains | Overweight | $294 → $292 |
| 2026-10-14 | Leerink Partners | Maintains | Outperform | $276 → $272 |
| 2026-10-14 | Wells Fargo | Maintains | Overweight | $282 → $275 |
| 2026-10-14 | RBC Capital | Maintains | Outperform | $290 → $280 |
| 2026-10-07 | Guggenheim | Reiterates | Buy | $287 |
| 2026-10-06 | RBC Capital | Maintains | Outperform | $287 → $290 |
| 2026-10-05 | Citigroup | Maintains | Buy | $298 → $303 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 53 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 0.5% below the 50-day MA ($265.02).
- bullish: Price vs 200-day MA: Trading 8.2% above the 200-day MA ($243.74).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+1.12) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($181.90) and high ($278.43).
JNJ Price Chart
Loading chart for JNJ…
Fundamentals
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
More in Drug Manufacturers - General
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.